
Tracon Pharmaceuticals
US-based TRACON Pharmaceuticals develops and commercializes targeted therapeutics for cancer and age-related diseases.

US-based TRACON Pharmaceuticals develops and commercializes targeted therapeutics for cancer and age-related diseases.
Founded in San Diego, TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel targeted therapeutics for cancer and age-related diseases. The company's core mission is to address unmet medical needs by leveraging endoglin biology to create antibodies that bind to the endoglin receptor. TRACON's lead product candidate, envafolimab, is a PD-L1 antibody aimed at treating sarcoma, positioning the company within the oncology and age-related disease markets.
TRACON Pharmaceuticals has garnered attention through its innovative approach and strategic focus on targeted therapies. Notable figures affiliated with the company include its experienced leadership team and scientific advisors who bring extensive expertise in biopharmaceutical development. The company has achieved significant milestones, including advancing envafolimab through clinical trials. Overall, TRACON's impact lies in its potential to offer new therapeutic options for patients with cancer and other serious conditions, contributing to the advancement of medical science in these critical areas.
Companies similar to Tracon Pharmaceuticals include Tallac Therapeutics, Crinetics Pharmaceuticals, Janux Therapeutics and Tract Therapeutics.
Tracon Pharmaceuticals was founded in 2004.
Tracon Pharmaceuticals' headquarters is located in San Diego, CA, US.
Tracon Pharmaceuticals' most recent funding round was for $30M (USD) in December 2022.
As of Dec 27, 2022, Tracon Pharmaceuticals has disclosed funding of $113M (USD). Undisclosed round amounts are excluded.
Tracon Pharmaceuticals has 18 employees as of Feb 6, 2024.

Tract Therapeutics